Cell 496 model predicts that streptolydigin should trap NTP in the pre-insertion site in such an elongation complex structure. Additionally, this cocrystal would be of great interest because it might reveal a specific role for the trigger loop in nucleotide binding or insertion. Since it is often disordered in RNAP crystal structures, the highly flexible trigger loop has received less attention as a key player in the nucleotide addition cycle. However, the structural element most affected by streptolydigin is this highly conserved loop (its position shifts by at least 11 Å upon streptolydigin binding), whose position in apo-RNAP clashes extensively with bound streptolydigin. Interestingly, Temiakov et al. report that deletion of the trigger loop inhibits nucleotide addition more than 10,000-fold, but that the residual activity is actually stimulated by streptolydigin binding. One wonders if this hints at a direct role of the trigger loop in nucleotide addition and in the mechanism of streptolydigin inhibition that remains underappreciated owing to its elusive location in many RNAP structures. In neurons, classic synaptic vesicles house small molecule neurotransmitters, such as acetylcholine or glutamate, and mediate rapid Ca 2+ -triggered release of neurotransmitter packets into the synaptic cleft. Synaptic vesicles spend their life at the nerve terminal where, in response to depolarization, they undergo exocytosis and are subsequently recycled from the plasma membrane. Neurons also contain large dense-core vesicles (LDCVs), which are Golgi-derived neuropeptide-rich units that belong to the so-called "regulated" arm of the protein secretory pathway (Arvan and Castle, 1998; Kelly, 1985). In addition to mediating neuropeptide release, LDCVs shuttle cell-surface receptors to the presynaptic plasma membrane in response to an excitatory stimulus. However, it is not clear how these receptors are directed preferentially to LDCVs, rather than to the ubiquitous or "constitutive" secretory pathway that carries housekeeping proteins to the cell surface. In this issue, Guan et al. (2005) provide tantalizing evidence that this sorting is accomplished through specific interactions between two constituents of the LDCV cargo. They show that protachykinin, the precursor of the neuropeptide substance P, binds to the G proteincoupled δ-opioid receptor and regulates the trafficking of this receptor in primary afferent neurons of the pain pathway. Importantly, substance P is not considered to be a physiological ligand for the δ-opioid receptor, which is activated by endogenous opioid peptides, such as enkephalin.
A Neuropeptide Courier for ␦-Opioid Receptors?
The ␦-opioid receptor and the precursor protein of a neuropeptide, substance P, are colocalized in the large dense-core vesicles of pain-sensing neurons. In this issue of Cell, Guan et al. (2005) report that trafficking of the ␦-opioid receptor to these vesicles depends on its physical interaction with the substance P domain of its precursor polyprotein (protachykinin). Moreover, in mice lacking this precursor, the contribution of the ␦-opioid receptor to pain processing is dramatically altered. These observations suggest a new role for peptide precursors as sorting signals in vesicular transport.
In neurons, classic synaptic vesicles house small molecule neurotransmitters, such as acetylcholine or glutamate, and mediate rapid Ca 2+ -triggered release of neurotransmitter packets into the synaptic cleft. Synaptic vesicles spend their life at the nerve terminal where, in response to depolarization, they undergo exocytosis and are subsequently recycled from the plasma membrane. Neurons also contain large dense-core vesicles (LDCVs), which are Golgi-derived neuropeptide-rich units that belong to the so-called "regulated" arm of the protein secretory pathway (Arvan and Castle, 1998; Kelly, 1985). In addition to mediating neuropeptide release, LDCVs shuttle cell-surface receptors to the presynaptic plasma membrane in response to an excitatory stimulus. However, it is not clear how these receptors are directed preferentially to LDCVs, rather than to the ubiquitous or "constitutive" secretory pathway that carries housekeeping proteins to the cell surface. In this issue, Guan et al. (2005) provide tantalizing evidence that this sorting is accomplished through specific interactions between two constituents of the LDCV cargo. They show that protachykinin, the precursor of the neuropeptide substance P, binds to the G proteincoupled δ-opioid receptor and regulates the trafficking of this receptor in primary afferent neurons of the pain pathway. Importantly, substance P is not considered to be a physiological ligand for the δ-opioid receptor, which is activated by endogenous opioid peptides, such as enkephalin.
The critical observation in this study comes from the analysis of mice lacking the preprotachykinin A (PPT-A) gene, which encodes a polyprotein precursor that is proteolytically processed to generate the neuropeptides, substance P and neurokinin A (Nawa et al., 1983). When noxious stimuli activate sensory nerve endings in the skin or other peripheral organs, LDCVs release substance P from presynaptic terminals within the spinal cord dorsal horn, leading to enhancement of nociceptive ( One surprising observation is that the interaction between the δ-opioid receptor and the PPT-A protein is determined primarily by the substance P domain within the precursor polypeptide. Whether the surrounding precursor sequence contributes to or facilitates this interaction, perhaps by presenting substance P to the δ-opioid receptor in an efficient membrane-associated configuration, is still not clear. The authors show that radiolabeled mature substance P can bind to an extracellular domain of the δ-opioid receptor (Guan et al.,  2005) . Presumably, this interaction is of low affinity as all specific binding of substance P in the central nervous system is lost in mice that lack the substance P receptor. Regardless, the structural underpinnings of this peptide-receptor interaction, as well as measurements of its strength and specificity, merit further analysis. These issues may be important in considering whether the mechanism proposed by Guan et al. depends on the presence of highly concentrated material within the LDCV, which would be reminiscent of aggregation-based models of protein sorting (Kelly, 1985) .
A key question addressed by Guan et al. (2005) concerns the amount of δ-opioid receptor that is transported from the cell body to the synaptic terminals of the pain-sensing neurons and the functional significance of the trafficking of this receptor via either the regulated LDCV or the constitutive secretory pathway. The authors used immunocytochemistry to localize the δ-opioid receptor in the superficial dorsal horn of the PPT-A mutant mice and found a very large decrease in staining. On the other hand, there was only a small decrease in binding of radiolabeled δ-opioid receptor agonists in PPT-A mutant mice. Taken together, these data indicate that in the absence of substance P, the δ-opioid receptor is shunted to the constitutive secretory pathway. However, the discrepancy between δ-opioid receptor detection by immunostaining and radioligand binding suggests that the contribution of the constitutive pathway to plasma membrane δ-opioid receptors in wild-type as well as mutant mice may be underestimated using immunocytochemistry. With respect to the functional significance of the two pathways, Guan et al. show that intrathecal administration (injection into the cerebrospinal fluid of the lumbar spinal cord) of a selective δ-opioid receptor agonist produces a profound analgesia in a test of heat-evoked pain. As the δ-opioid receptor is primarily expressed by the primary afferent pain fibers, this analgesic action is presumed to result from a presynaptic inhibition of Ca 2+ channels mediated by the δ-opioid receptor (Acosta and Lopez, 1999) and a resultant decrease in neurotransmitter release from the primary afferent terminal onto spinal cord "pain"-transmission neurons. Because the analgesic action of a δ-opioid receptor agonist completely disappeared in PPT-A mutant mice, it follows that any plasma membrane expression of the δ-opioid receptor that arises from the constitutive pathway must be nonfunctional, or at least is not coupled to Ca 2+ channels in the same way as the δ-opioid receptors that arrive via the regulated pathway. This is a puzzling result that begs further analysis. It would be of interest, for example, to assess the effect of δ-opioid receptor agonists on Ca 2+ channel function in sensory neurons taken from PPT-A mutant mice.
There is another very important paradox concerning the function of δ-opioid receptors in the plasma mem-brane. In a previous study, this group reported that δ-opioid receptor agonists stimulate movement of LDCVs to the plasma membrane, via an increase in intracellular calcium ions, and that this results in exocytosis of the LDCV and release of its peptide contents (Bao et al., 2003) . Because the peptide content is largely pronociceptive (pain enhancing), the authors conclude that the treatment of pain might be improved by administering a δ-opioid receptor antagonist. How can these observations be made concordant with the fact that a δ-opioid receptor agonist is analgesic in wild-type animals? Perhaps a δ-opioid receptor agonist concurrently evokes release of pronociceptive mediators while inhibiting their release over a longer time course.
The complexity of δ-opioid receptor activity is further illustrated by the observation that the efficacy of morphine, which acts via the subtype of opioid receptor, is enhanced in the PPT-A mutant mice (Guan et al. 
